(24/7 MARKET NEWS) – SQZ Biotechnologies Company (NYSE: SQZ) announced, after yesterday’s market close, that, according to RECIST 1.1 criteria, a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial and the company decided to continue to enroll patients in this clinical trial, including the second and third patients have also been enrolled in the trial.
SQZ Biotechnologies is trading at $0.72, up $0.11 (20.12%), on 3.3 million premarket shares.
Its 52-week trading range is $0.53 to $5.20. Its next key resistance levels are $0.87, $0.90 and $1.01. If it can break through the $1.01 resistance, on strong trading volume, it could set up for a potential run to the mid $2 level or higher.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
